<?xml version="1.0" encoding="UTF-8"?>
<GaPExchange xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:noNamespaceSchemaLocation="./dbGaPEx2.1.5.xsd">

<MetaVariables>
	<Submitter/>
	<Method/>
</MetaVariables>
<MetaLinks/>

<Projects>
	<Project/>
</Projects>

<Studies>

<Study source="dbGaP" accession="phs001257.v1.p1" parentStudy="phs001257.v1.p1" createDate="2016-12-12" modDate="2016-12-16">

<Configuration>
	<Data_Provider><![CDATA[
		<table border="1">
		<tr><th>Title</th><th>Name</th><th>Institute</th></tr>
		<tr><td>Principal Investigators</td><td>Andy Futreal, PhD</td><td>UT MD Anderson Cancer Center, Houston, TX, USA</td></tr>
		<tr><td>Principal Investigators</td><td>Jennifer Wargo, MD</td><td>UT MD Anderson Cancer Center, Houston, TX, USA</td></tr>
		<tr><td>Funding Source</td><td>5U54CA163125-04</td><td>National Cancer Institute, National Institutes of Health, Bethesda, MD, USA</td></tr>
		</table>
	]]></Data_Provider>
	<StudyNameEntrez>Genetic Analysis of Tumor Samples</StudyNameEntrez>
	<StudyNameReportPage>Loss of IFN-gamma Signaling in Tumor Cells Associates with Primary Resistance to Anti-CTLA-4 Therapy</StudyNameReportPage>
	<StudyTypes>
		<StudyType>Case Set</StudyType>
	</StudyTypes>
	<Description><![CDATA[
<p>Antibody blockade of the inhibitory CTLA-4 pathway has led to clinical benefit in a subset of patients with metastatic melanoma. Anti-CTLA-4 enhances T cell responses, including production of IFN-&#947;, which is a critical cytokine for host immune responses. However, the role of IFN-&#947; signaling in tumor cells in the setting of anti-CTLA-4 therapy remains unknown. Here we demonstrate that, based upon exome sequencing data, patients identified as non-responders to anti-CTLA-4 (ipilimumab) harbor a much higher genomic defects in the IFN-&#947; pathway genes than melanoma patients who had clinical response to ipilimumab therapy.</p>]]>
	</Description>
	<StudyProjects>
		<Project/>
	</StudyProjects>
	<Publications>
		<Publication>
			<Pubmed pmid="27667683"/>
		</Publication>
	</Publications>
	<Diseases>
		<Disease vocab_source="MESH" vocab_term="Melanoma"/>
	</Diseases>
	<Attributions>
		<Header title="Principal Investigators">
			<AttName>Andy Futreal, PhD</AttName>
			<Institution>UT MD Anderson Cancer Center, Houston, TX, USA</Institution>
		</Header>
		<Header title="Principal Investigators">
			<AttName>Jennifer Wargo, MD</AttName>
			<Institution>UT MD Anderson Cancer Center, Houston, TX, USA</Institution>
		</Header>
		<Header title="Funding Source">
			<AttName>5U54CA163125-04</AttName>
			<Institution>National Cancer Institute, National Institutes of Health, Bethesda, MD, USA</Institution>
		</Header>
	</Attributions>
	<DisplayPublicSummary>yes</DisplayPublicSummary>
	<ConsentGroups>
		<ConsentGroup groupNum="1" shortName="DS-M-PUB-NPU" longName="Disease-Specific (Melanoma, PUB, NPU)"/>
	</ConsentGroups>
</Configuration>

  <AuthorizedAccess>
    <DacInfo ssDacId="0">
      <DacName>NCI</DacName>
      <DacFullName>NCI</DacFullName>
      <DacEmail>0</DacEmail>
      <DacPhone></DacPhone>
      <DacUrl></DacUrl>
    </DacInfo>
    <Policy Policy_ID="phs001257.v1.p1_policy" ref_ssDacId="0">
      <DisplayResearchStatement>yes</DisplayResearchStatement>
      <DisplayPublicSummary>yes</DisplayPublicSummary>
      <EmbargoLength>0</EmbargoLength>
      <YearsUntilRenewal>1</YearsUntilRenewal>
      <WeeksCancelRequest>8</WeeksCancelRequest>
      <PdfSupplementReqired>no</PdfSupplementReqired>
      <AcknowledgementText>
        <para>
          http://dbgap.ncbi.nlm.nih.gov/aa/wga.cgi?page=DUC&amp;view_pdf&amp;stacc=phs001257.v1.p1
        </para>
      </AcknowledgementText>
      <DocumentSet>
        <DataUseCertificate Label="Data Use Certificate" FilePath="https://dbgap.ncbi.nlm.nih.gov/aa/wga.cgi?page=DUC&amp;view_pdf&amp;stacc=phs001257.v1.p1" FileName=""/>
      </DocumentSet>
    </Policy>
    <ConsentGroups>
      <ParticipantSet groupNum-REF="1">
        <ConsentName>Disease-Specific (Melanoma, PUB, NPU)</ConsentName>
        <ConsentAbbrev>DS-M-PUB-NPU</ConsentAbbrev>
        <UseLimitation>Use of the data must be related to Melanoma.
Requestor agrees to make results of studies using the data available to the larger scientific community.
Use of the data is limited to not-for-profit organizations.</UseLimitation>
        <IrbRequired>No</IrbRequired>
      </ParticipantSet>
    </ConsentGroups>
  </AuthorizedAccess>


</Study>

</Studies>

</GaPExchange>
